Evidence map›Paper›PMID 34838714›Full record

ArticleMolecular metabolism2022

The activity of glyoxylase 1 is regulated by glucose-responsive phosphorylation on Tyr136.

Fabiola Garcia Cortizo, Daniel Pfaff, Angela Wirth, Andrea Schlotterer, Rebekka Medert, Jakob Morgenstern, Tobias Weber, Hans-Peter Hammes, Thomas Fleming, Peter Paul Nawroth and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. A putativeFrontiers in immunology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Fabiola Garcia CortizoGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany; Heidelberg University, 69120, Heidelberg, Germany.
Daniel PfaffGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany; Department of Internal Medicine I and Clinical Chemistry, University Hospital Heidelberg, Germany.
Angela WirthPharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany.
Andrea Schlotterer5th Medical Department, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany.
Rebekka MedertPharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany.
Jakob MorgensternDepartment of Internal Medicine I and Clinical Chemistry, University Hospital Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.
Tobias WeberGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany; Heidelberg University, 69120, Heidelberg, Germany.
Hans-Peter Hammes5th Medical Department, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany.
Thomas FlemingDepartment of Internal Medicine I and Clinical Chemistry, University Hospital Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.
Peter Paul NawrothDepartment of Internal Medicine I and Clinical Chemistry, University Hospital Heidelberg, Germany.
Marc FreichelPharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany.
Aurelio A TelemanGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany; Heidelberg University, 69120, Heidelberg, Germany. Electronic address: a.teleman@dkfz.de.
Heidelberg University · DEUniversity Hospital Heidelberg · DEGerman Cancer Research Center · DE

Funding

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
NIGMS NIH HHS R01 GM129325
6 · The paper itself

Abstract

objectiveMethylglyoxal (MG) is a highly reactive α-oxoaldehyde that glycates proteins. MG has been linked to the development of diabetic complications: MG is the major precursor of advanced glycation end products (AGEs), a risk marker for diabetic complications in humans. Furthermore, flies and fish with elevated MG develop insulin resistance, obesity, and hyperglycemia. MG is detoxified in large part through the glyoxalase system, whose rate-limiting enzyme is glyoxalase I (Glo1). Hence, we aimed to study how Glo1 activity is regulated.

methodsWe studied the regulation and effect of post-translational modifications of Glo1 in tissue culture and in mouse models of diabetes.

resultsWe show that Glo1 activity is promoted by phosphorylation on Tyrosine 136 via multiple kinases. We find that Glo1 Y136 phosphorylation responds in a bimodal fashion to glucose levels, increasing in cell culture from 0 mM to 5 mM (physiological) glucose, and then decreasing at higher glucose concentrations, both in cell culture and in mouse models of hyperglycemia.

conclusionsThese data, together with published findings that elevated MG leads to hyperglycemia, suggest the existence of a deleterious positive feedback loop whereby hyperglycemia leads to reduced Glo1 activity, contributing to elevated MG levels, which in turn promote hyperglycemia. Hence, perturbations elevating either glucose or MG have the potential to start an auto-amplifying feedback loop contributing to diabetic complications.

Indexed as

AnimalsDiabetes ComplicationsDiabetes MellitusGlucoseGlycation End Products, AdvancedHEK293 CellsHeLa CellsHep G2 CellsHumansHyperglycemiaLactoylglutathione LyaseMiceMice, Inbred C57BLObesityPhosphorylationPyruvaldehydeGLO1 protein, humanGlucoseGlycation End Products, AdvancedLactoylglutathione LyasePyruvaldehydeDiabetesGlyoxalasePhosphorylation

Identifiers

PMID34838714
PMCPMC8715127
OpenAlexW3215655262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.